Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Protection against Dynorphin-(1–8) Hydrolysis in Membrane Preparations by the Combination of Amastatin, Captopril and Phosphoramidon

Toyokazu Hiranuma, Ken Kitamura, Takao Taniguchi, Masayuki Kanai, Yoshiharu Arai, Kayoko Iwao and Tetsuo Oka
Journal of Pharmacology and Experimental Therapeutics August 1998, 286 (2) 863-869;
Toyokazu Hiranuma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Kitamura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takao Taniguchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masayuki Kanai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshiharu Arai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kayoko Iwao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tetsuo Oka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The amounts of dynorphin-(1–8) [dyn-(1–8)] and its seven hydrolysis products, Y, YG, YGG, YGGF, YGGFL, YGGFLR and YGGFLRR, were estimated after incubating dyn-(1–8) with a membrane fraction from either guinea-pig ileum or striatum for various times at 37°C. The major hydrolysis products during the initial 5-min incubation were YGGFLR and Y, which indicates that dipeptidyl carboxypeptidase and aminopeptidase activities were mainly involved in the hydrolysis. After 60 min of incubation, dyn-(1–8) was completely hydrolyzed in both membrane preparations. When the ileal and the striatal preparations were incubated for 60 min in the presence of both captopril, a dipeptidyl carboxypeptidase inhibitor, and amastatin, an aminopeptidase inhibitor, 63.8 and 49.3% of dyn-(1–8), respectively, were hydrolyzed. The YGG fragment was the major hydrolysis product in both preparations. When the ileal and the striatal membrane fractions were incubated with dyn-(1–8) in the presence of three peptidase inhibitors, captopril, amastatin and phosphoramidon (an inhibitor of endopeptidase-24.11), approximately 95% of the opioid octapeptide remained intact in both cases. This shows that dyn-(1–8) was almost exclusively hydrolyzed by three enzymes, amastatin-sensitive aminopeptidase, captopril-sensitive dipeptidyl carboxypeptidase I and phosphoramidon-sensitive endopeptidase-24.11, in both ileal and striatal membranes. Additionally, the Ke (equilibrium dissociation constant) values of selective antagonists against dyn-(1–8) and its initial main hydrolysis product YGGFLR in two isolated preparations pretreated with the three peptidase inhibitors indicate that the latter acts onmu receptors in guinea pig ileum but deltareceptors in mouse vas deferens and the former acts on kappareceptors in both preparations. It is indicated, therefore, that in the absence of peptidase inhibitors endogenously released dyn-(1–8) acts either through dyn-(1–8) itself on kappa receptors or through YGGFLR on mu or delta receptors depending on both the three peptidase activities and the three receptor type densities at the target synaptic membrane.

Footnotes

  • Send reprint requests to: Dr. Tetsuo Oka, Department of Pharmacology, School of Medicine, Tokai University, Isehara 259-11, Japan.

  • ↵1 This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan.

  • Abbreviations:
    dyn-(1–8) and -(1–17)
    dynorphin-(1–8) and -(1–17)
    AsA
    amastatin-sensitive aminopeptidase(s)
    PsE
    phosphoramidon-sensitive endopeptidase-24.11 (“enkephalinase”, EC3.4.24.11)
    CsD
    captopril-sensitive dipeptidyl carboxypeptidase I (angiotensin 1 converting enzyme, kininase II, EC 3.4.15.1)
    met-enk
    [Met5]-enkephalin
    met-enk-RGL
    [Met5]-enkephalin-Arg6-Gly7-Leu8
    PI
    peptidase inhibitor
    DAMGO
    [d-Ala2,N-Me-Phe4,Gly-ol]-enkephalin
    DPDPE
    [d-Pen2,5]-enkephalin
    CTOP
    d-Phe-Cys-Tyr-d-Trp-Orn-Thr-Pen-Thr-NH2
    nor-BNI
    nor-binaltorphimine HCl tetrahydrate
    ICI-174
    864,N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH (Aib = α-aminoisobutyric acid)
    HPLC-ECD
    high-performance liquid chromatography combined with electrochemical detection
    The standard one-letter
    instead of three-letter, codes for amino acids were employed for the hydrolysis products of dyn-(1–8)
    • Received January 28, 1998.
    • Accepted April 10, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 286, Issue 2
1 Aug 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Protection against Dynorphin-(1–8) Hydrolysis in Membrane Preparations by the Combination of Amastatin, Captopril and Phosphoramidon
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Protection against Dynorphin-(1–8) Hydrolysis in Membrane Preparations by the Combination of Amastatin, Captopril and Phosphoramidon

Toyokazu Hiranuma, Ken Kitamura, Takao Taniguchi, Masayuki Kanai, Yoshiharu Arai, Kayoko Iwao and Tetsuo Oka
Journal of Pharmacology and Experimental Therapeutics August 1, 1998, 286 (2) 863-869;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Protection against Dynorphin-(1–8) Hydrolysis in Membrane Preparations by the Combination of Amastatin, Captopril and Phosphoramidon

Toyokazu Hiranuma, Ken Kitamura, Takao Taniguchi, Masayuki Kanai, Yoshiharu Arai, Kayoko Iwao and Tetsuo Oka
Journal of Pharmacology and Experimental Therapeutics August 1, 1998, 286 (2) 863-869;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PST3093 Stimulates SERCA2a and Improves Cardiac Function
  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Is Hydroxylamine-Induced Cytotoxicity a Valid Marker for Hypersensitivity Reactions to Sulfamethoxazole in Human Immunodeficiency Virus-Infected Individuals?
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics